Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Vancouver Coastal Health Research Institute | OTHER |
| Simon Fraser University | OTHER |
| St. Paul's Hospital, Canada | OTHER |
| Providence Health & Services |
Not provided
Not provided
Not provided
The goal of this interventional clinical research study is to assess the efficacy of a 12-week precision exercise training intervention to improve exercise tolerance in sepsis survivors.
The main question it aims to answer is does a 12-week precision exercise training program improve constant load exercise time in sepsis survivors?
Participants will:
Researchers will compare the exercise group to an attention control group of sepsis survivors who do not receive exercise training but instead undergo usual care procedures and receive general lifestyle advice 1x per week.
Sepsis is a life threatening condition that results in multi-organ system dysfunction. In those who survive sepsis, many patients present with chronic immune dysregulation (i.e., paradoxical hyperinflammation and immune suppression), leading to high rates of re-hospitalization. In addition, exercise tolerance is significantly reduced both acutely post hospital discharge and long term (~5 years post initial infection). Exercise training is a pleiotropic intervention that has been demonstrated to improve exercise tolerance in a multitude of clinical populations. Aerobic exercise training is also associated with anti-inflammatory and immune-enhancing effects; however, the magnitude of these immunological adaptations is largely dependent on the exercise prescription used. To date, exercise training studies in sepsis have used a more traditional generic linear exercise training approach, which has resulted in minimal or no effect on exercise tolerance. This is in contrast to other clinical populations wherein precision exercise training (e.g., individualized, nonlinear periodized, combined aerobic and strength training) has resulted in greater improvements in exercise tolerance compared to non-specific linear exercise programs, and is considered safe and tolerable. To date, no study has sought to investigate the effects of a precision exercise training intervention on exercise tolerance and immune function in sepsis survivors.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Exercise Intervention | Experimental | Patients will participate in a 12-week (36 sessions) precision exercise training intervention |
|
| Attention Control | No Intervention | Patients will not receive exercise training but will be contacted 1x per week via phone to document self-reported physical activity and general wellbeing. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 12-week precision exercise training | Other | The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in constant load exercise time | Individuals will complete a constant-load exercise trial to symptom limitation at ~70% workload maximum (determined by a cardiopulmonary exercise test) on a cycle ergometer pre to post 12-weeks of the intervention period. The primary outcome will be change in time from pre to post test. | 12-weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in health related quality of life (SF-36) | The change in health related quality of life measured by the SF-36 component scores pre to post 12-weeks of the intervention period. The SF 36 Medical Outcomes Study Survey (SF-36) is a 36-item survey that measures quality of life over eight domains, including physical functioning, bodily pain, limitations due to physical health problems, limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue and general health perceptions. Pre-coded numeric values are assigned to each scale, with items scored from 0-100. High scores represent a more favourable health state. Items in each domain are also averaged to create eight separate domain scores. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in clinical biomarkers of immune function (highly sensitive C-reactive protein) | The change in highly sensitive C-reactive protein (mg/L) pre to post 12-weeks of the intervention period. | 12-weeks |
| Change in clinical biomarkers of immune function (absolute lymphocyte count) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Graeme Koelwyn, PhD | Contact | 604-682-2344 | 66221 | graeme.koelwyn@hli.ubc.ca |
| John Boyd, MD | Contact | 604-682-2344 | 63047 | john.boyd@hli.ubc.ca |
| Name | Affiliation | Role |
|---|---|---|
| Graeme Koelwyn, PhD | University of British Columbia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Paul's Hospital - Centre for Heart Lung Innovation | Recruiting | Vancouver | British Columbia | Canada |
Deidentified individual participant data will be made available as required by a condition of awards and agreements supporting the research.
12 months after publication and for up to 36 months post publication
The investigator who proposed to use the data and upon reasonable request. Requests should be directed to graeme.koelwyn@hli.ubc.ca. To gain access, data requestors will need to sign a data access agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| 12-weeks |
The change in absolute lymphocyte count (per mL) pre to post 12-weeks of the intervention period. |
| 12-weeks |
| Change in clinical biomarkers of immune function (monocyte HLA-DR) | The change in monocyte human leukocyte antigen-DR (per cell) pre to post 12-weeks of the intervention period. | 12-weeks |
| D013568 |
| Pathological Conditions, Signs and Symptoms |